WHO ICTRP trial
A Phase II clinical study to evaluate the efficacy and safety of pleural…
ChiCTR2300077573 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300077573 |
|---|---|
| Public title | A Phase II clinical study to evaluate the efficacy and safety of pleural perfusion of recombinant modified human tumor necrosis factor combined with sindrelimab plus chemotherapy in first-line treatment of driver negative non-squamous non-small cell lung cancer (NSCLC) with malignant pleural effusion |
| Scientific title | A Phase II clinical study to evaluate the efficacy and safety of pleural perfusion of recombinant modified human tumor necrosis factor combined with sindrelimab plus chemotherapy in first-line treatment of driver negative non-squamous non-small cell lung cancer (NSCLC) with malignant pleural… |
| Primary sponsor | Affiliated Cancer Hospital of Shandong First Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Lung Cancer |
| Interventions | experimental group:Tianfu thoracic perfusion combined with sindillizumab + chemotherapy, every 3 weeks (21 days) for a treatment cycle |
| Registration date | Nov 13, 2023 |
| Target size | experimental group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: